前沿生物-U
(688221)
| 流通市值：52.52亿 | | | 总市值：52.52亿 |
| 流通股本：3.75亿 | | | 总股本：3.75亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 58,639,825.88 | 28,328,182.53 | 129,472,935.98 | 91,643,894.39 |
| 营业收入 | 58,639,825.88 | 28,328,182.53 | 129,472,935.98 | 91,643,894.39 |
| 二、营业总成本 | 159,170,063.11 | 74,909,155.77 | 405,686,029.6 | 282,018,728.06 |
| 营业成本 | 40,468,036.68 | 19,130,499.87 | 85,546,537.91 | 60,953,794.67 |
| 税金及附加 | 1,564,162.01 | 775,150.96 | 4,597,169.4 | 3,633,349.39 |
| 销售费用 | 37,676,114.99 | 21,243,275.06 | 86,344,001.84 | 47,921,544.66 |
| 管理费用 | 32,416,374.22 | 17,144,817.33 | 84,816,363.24 | 52,388,599.62 |
| 研发费用 | 47,936,469.2 | 16,803,233.38 | 137,205,648.06 | 109,341,964.29 |
| 财务费用 | -891,093.99 | -187,820.83 | 7,176,309.15 | 7,779,475.43 |
| 其中:利息费用 | 4,670,816.41 | 2,363,345.93 | 10,271,685.7 | 7,916,503.87 |
| 其中:利息收入 | 5,901,767.72 | 2,804,501.34 | 4,120,130.85 | 1,801,887.66 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -297,011.44 | -206,446.41 | 83,505.51 | 991,376.04 |
| 加:投资收益 | -1,861,944.89 | 461,621.71 | 84,091,885.06 | 11,638,399.52 |
| 资产处置收益 | 15,353.93 | 15,353.93 | 18,798.64 | 18,798.64 |
| 资产减值损失(新) | -89,923.13 | -152,429.13 | -46,727,551.35 | -41,141,862.41 |
| 信用减值损失(新) | -1,443,018.17 | -897,500.57 | 253,226.64 | -1,470,354.38 |
| 其他收益 | 7,058,376.99 | 3,224,253.28 | 37,399,668.2 | 27,143,391.83 |
| 四、营业利润 | -97,148,403.94 | -44,136,120.43 | -201,093,560.92 | -193,195,084.43 |
| 加:营业外收入 | 21,040.01 | 16,187.67 | 22,845.66 | 20,499.13 |
| 减:营业外支出 | 225,246.75 | 1,584.65 | 311,895.13 | 283,168.87 |
| 五、利润总额 | -97,352,610.68 | -44,121,517.41 | -201,382,610.39 | -193,457,754.17 |
| 六、净利润 | -97,352,610.68 | -44,121,517.41 | -201,382,610.39 | -193,457,754.17 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -97,352,610.68 | -44,121,517.41 | -201,382,610.39 | -193,457,754.17 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -97,352,610.68 | -44,121,517.41 | -201,382,610.39 | -193,457,754.17 |
| 扣除非经常损益后的净利润 | -114,735,072.42 | -53,145,687.62 | -327,311,199.95 | -232,987,050.46 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.26 | -0.12 | -0.54 | -0.52 |
| (二)稀释每股收益 | -0.26 | -0.12 | -0.54 | -0.52 |
| 八、其他综合收益 | 16,756.4 | 21,559.46 | 11,919.84 | -9,917.82 |
| 归属于母公司股东的其他综合收益 | 16,756.4 | 21,559.46 | 11,919.84 | -9,917.82 |
| 九、综合收益总额 | -97,335,854.28 | -44,099,957.95 | -201,370,690.55 | -193,467,671.99 |
| 归属于母公司股东的综合收益总额 | -97,335,854.28 | -44,099,957.95 | -201,370,690.55 | -193,467,671.99 |
| 公告日期 | 2025-08-30 | 2025-04-30 | 2025-04-30 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |